News

• December 22, 2022
  Targovax announces that the TG01 study in multiple myeloma at Oslo University Hospital has received regulatory approvals to proceed
• December 20, 2022
  Targovax ASA issues options to employees
• December 15, 2022
  Targovax announces clinical trial collaboration with Agenus to test TG mutant RAS vaccination in pancreatic cancer
• December 7, 2022
  Targovax to present and attend at upcoming conferences

All news

Company presentations

• Company presentation January 2023

Events

• February 16, 2023 Quarterly Report Q4 Add to Calendar
• March 8, 2023 Annual Report Add to Calendar
• April 20, 2023 Annual General Meeting 2023 Add to Calendar

All events

Mesothelioma 30-month data

The 30-month data from the mesothelioma trial was released December 2021. See press release here.
For a video presentation of the 24-month data from June 2021, please see links below:

• English
• Norwegian

Q3 interim report 2022

Targovax ASA (OSE: TRVX) announced its third quarter 2022 results on Thursday 3 November 2022. Targovax’s management will present the results at a live streamed webcast at 10:00 am CET to investors, analysts and the press. 

• Report
• Presentation
• Webcast

Read the report

Webcast presentation on Xtrainvestor

For a company presentation in Norwegian, please see video below.

• Webcast

Share price